{"id":"https://openalex.org/W2398096659","doi":"https://doi.org/10.1200/jco.2015.33.7_suppl.221","title":"ODM-204: A novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer\u2014Preclinical data.","display_name":"ODM-204: A novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer\u2014Preclinical data.","publication_year":2015,"publication_date":"2015-03-01","ids":{"openalex":"https://openalex.org/W2398096659","doi":"https://doi.org/10.1200/jco.2015.33.7_suppl.221","mag":"2398096659"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.7_suppl.221","doi":"https://doi.org/10.1200/jco.2015.33.7_suppl.221","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.7_suppl.221","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082795809","display_name":"Riikka Oksala","orcid":"https://orcid.org/0000-0001-6256-562X","observed_orcids":["https://orcid.org/0000-0001-6256-562X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Riikka Oksala","raw_affiliation_strings":["Orion Pharmaceuticals Corporation, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Pharmaceuticals Corporation, Turku, Finland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110172886","display_name":"Anu Moilanen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anu Moilanen","raw_affiliation_strings":["Orion Pharmaceuticals Corporation, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Pharmaceuticals Corporation, Turku, Finland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085172744","display_name":"Reetta Riikonen","orcid":"https://orcid.org/0000-0003-0485-0064","observed_orcids":["https://orcid.org/0000-0003-0485-0064"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Reetta Riikonen","raw_affiliation_strings":["Orion Corporation Orion Pharma, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003827984","display_name":"Petteri Rummakko","orcid":"https://orcid.org/0000-0002-0020-4068","observed_orcids":["https://orcid.org/0000-0002-0020-4068"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Petteri Rummakko","raw_affiliation_strings":["Orion Corporation Orion Pharma, Espoo, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080497006","display_name":"Riikka Huhtaniemi","orcid":"https://orcid.org/0000-0002-5044-8933","observed_orcids":["https://orcid.org/0000-0002-5044-8933"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Riikka Huhtaniemi","raw_affiliation_strings":["Orion Corporation Orion Pharma, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016359992","display_name":"Pekka J. Kallio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Pekka Kallio","raw_affiliation_strings":["Orion Corporation Orion Pharma, Espoo, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland","institution_ids":["https://openalex.org/I4210118237"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"7_suppl","first_page":"221","last_page":"221"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11146","display_name":"Hormonal and reproductive studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.878000020980835},{"id":"https://openalex.org/keywords/androgen-receptor","display_name":"androgen receptor","score":0.8579999804496765},{"id":"https://openalex.org/keywords/cyp17a1","display_name":"CYP17A1","score":0.9869999885559082},{"id":"https://openalex.org/keywords/dual-inhibitors","display_name":"dual inhibitors","score":0.7910000085830688},{"id":"https://openalex.org/keywords/androgen-biosynthesis-inhibition","display_name":"androgen biosynthesis inhibition","score":0.824999988079071},{"id":"https://openalex.org/keywords/non-steroidal-inhibitors","display_name":"non-steroidal inhibitors","score":0.7260000109672546},{"id":"https://openalex.org/keywords/nuclear-translocation","display_name":"nuclear translocation","score":0.7910000085830688},{"id":"https://openalex.org/keywords/vcap-xenograft","display_name":"VCaP xenograft","score":0.8600000143051147},{"id":"https://openalex.org/keywords/lncap-cells","display_name":"LNCaP cells","score":0.7889999747276306},{"id":"https://openalex.org/keywords/leuprolide-acetate","display_name":"leuprolide","score":0.8410000205039978},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.5770000219345093}],"concepts":[{"id":"https://openalex.org/C142716871","wikidata":"https://www.wikidata.org/wiki/Q408305","display_name":"CYP17A1","level":3,"score":0.765228271484375},{"id":"https://openalex.org/C1292079","wikidata":"https://www.wikidata.org/wiki/Q3817769","display_name":"Transactivation","level":4,"score":0.7597532272338867},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.7518474459648132},{"id":"https://openalex.org/C2779723316","wikidata":"https://www.wikidata.org/wiki/Q6459234","display_name":"LNCaP","level":4,"score":0.6843507289886475},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.5555037260055542},{"id":"https://openalex.org/C2777911890","wikidata":"https://www.wikidata.org/wiki/Q62614","display_name":"Androgen","level":3,"score":0.5330750942230225},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5053501725196838},{"id":"https://openalex.org/C2779279991","wikidata":"https://www.wikidata.org/wiki/Q6058681","display_name":"Testosterone (patch)","level":2,"score":0.4458179175853729},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44450142979621887},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4326784908771515},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.402109831571579},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.37453463673591614},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3511695861816406},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3317772150039673},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.2121778428554535},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1652052402496338},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.1474815309047699},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11995834112167358},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.7_suppl.221","doi":"https://doi.org/10.1200/jco.2015.33.7_suppl.221","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.7_suppl.221","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2471058813","https://openalex.org/W2598641564","https://openalex.org/W2793841534","https://openalex.org/W2261870911","https://openalex.org/W2515346734","https://openalex.org/W2762760566","https://openalex.org/W2898210525","https://openalex.org/W2886982466","https://openalex.org/W3175696952","https://openalex.org/W1902440608"],"abstract_inverted_index":{"221":[0],"Background:":[1],"Castration-resistant":[2],"prostate":[3,71],"cancer":[4],"(CRPC)":[5],"is":[6,39,195,299],"characterized":[7],"by":[8,21,154,160,295],"high":[9,210,219],"androgen":[10,28],"receptor":[11],"(AR)":[12],"expression":[13],"and":[14,27,47,76,94,106,115,129,134,163,167,174,202,214,216,234,243,248,252,261,289,305],"persistent":[15],"activation":[16],"of":[17,45,61,79,109,121,126,145,152,199,232,257,283,311],"AR":[18,26,66,83,93,103,111,201,207,233,306],"signaling":[19],"axis":[20],"residual":[22],"tissue/tumor":[23],"androgens.":[24],"Targeting":[25],"biosynthesis":[29],"together":[30],"may":[31],"be":[32,320],"more":[33],"effective":[34],"than":[35],"either":[36],"alone.":[37],"ODM-204":[38,62,80,122,155,194,227,271,298],"a":[40,168,196,209,218,267,300],"novel,":[41],"non-steroidal":[42],"dual":[43,303],"inhibitor":[44,198,307],"CYP17A1":[46,153,222,304],"AR,":[48],"which":[49],"has":[50,217],"shown":[51],"promising":[52,301],"results":[53],"in":[54,69,86,132,139,158,175,177,315,322],"preclinical":[55],"studies.":[56],"Methods:":[57],"The":[58,74,119,150],"binding":[59],"affinity":[60,211],"to":[63,81,189,206],"wild":[64],"type":[65],"was":[67,156],"determined":[68],"rat":[70,164],"cytosolic":[72],"lysates.":[73],"potency":[75,220],"functional":[77],"activity":[78,275],"human":[82,110,162,169],"were":[84,117,148,245,293],"demonstrated":[85],"cells":[87,131,138],"stably":[88],"transfected":[89],"with":[90,141,181,208,317],"the":[91,107,124,142,235,309],"full-length":[92],"androgen-responsive":[95],"reporter":[96],"gene":[97],"constructs.":[98],"In":[99,225,266,279],"addition,":[100,226],"assays":[101],"for":[102,240,308],"nuclear":[104,230],"translocation":[105,231],"transactivation":[108],"mutants":[112],"T877A,":[113],"W741L,":[114],"F876L":[116],"conducted.":[118],"effects":[120,282],"on":[123,286],"growth":[125,277],"androgen-dependent":[127],"VCaP":[128,137,262,268],"LNCaP":[130,258],"vitro":[133,159],"subcutaneously":[135],"grafted":[136],"vivo":[140,176],"oral":[143],"dose":[144],"50":[146],"mg/kg/day":[147],"studied.":[149],"inhibition":[151],"studied":[157],"using":[161],"testicular":[165],"microsomes":[166],"adrenal":[170],"cortex":[171],"cell":[172,255],"line,":[173],"male":[178],"rats":[179],"coadministered":[180],"luteinizing":[182],"hormone":[183,185],"releasing":[184],"agonist":[186],"leuprolide":[187,284],"acetate":[188,285],"mimic":[190],"clinical":[191],"situation.":[192],"Results:":[193],"potent":[197],"both":[200],"CYP17A1.":[203],"It":[204],"binds":[205],"(Ki=47":[212],"nM)":[213,260,264],"selectivity":[215],"towards":[221],"(IC50=22":[223],"nM).":[224],"inhibited":[228],"testosterone-mediated":[229],"mutant":[236],"ARs":[237],"(IC50":[238],"values":[239],"AR(T877A),":[241],"AR(W741L),":[242],"AR(F876L)":[244],"95,":[246],"277,":[247],"6":[249],"nM,":[250],"respectively),":[251],"suppressed":[253],"androgen-induced":[254],"proliferation":[256],"(IC50=170":[259],"(IC50=280":[263],"cells.":[265],"xenograft":[269],"model,":[270],"showed":[272],"significant":[273],"antitumor":[274],"(tumor":[276],"inhibition=66%).":[278],"rats,":[280],"inhibitory":[281],"testosterone":[287],"production":[288],"androgen-sensitive":[290],"organ":[291],"weights":[292],"potentiated":[294],"ODM-204.":[296],"Conclusions:":[297],"new":[302],"treatment":[310],"CRPC.":[312],"Clinical":[313],"trials":[314],"patients":[316],"mCRPC":[318],"will":[319],"started":[321],"early":[323],"2015.":[324]},"counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}